News - Antibiotics and Infectious diseases, isavuconazole

Filter

Popular Filters

Astellas submits NDA for isavuconazole to treat deadly fungal infections

Astellas submits NDA for isavuconazole to treat deadly fungal infections

10-07-2014

Japanese drug major Astellas Pharma has submitted a New Drug Application to the US Food and Drug Administration,…

Antibiotics and Infectious diseasesAntifungal therapiesAspergillosisAstellas PharmaBiologyFungal diseasesImmunologicalsInvasive aspergillosisisavuconazoleJapanMycologyPharmaceuticalRegulationZygomycosis

FDA calls for additional Ph III study for Basilea’s ceftobiprole

FDA calls for additional Ph III study for Basilea’s ceftobiprole

26-06-2014

Swiss drugmaker Basilea Pharmaceutica saw its shares drop as much as 12% yesterday, after it revealed…

Antibiotics and Infectious diseasesBacteriaBasilea PharmaceuticaceftobiproleHealth Medical PharmaHealth Medical PharmaisavuconazoleMedicinePharmaceuticalRegulationTreatment of pneumoniaUSA

Astellas amends license deal for isavuconazole with Basilea

01-03-2014

Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

Basilea updates on isavuconazole development

17-07-2013

Switzerland-based Basilea Pharmaceutica Ltd. (SIX: BSLN) provided an update today (July 17) on the Phase…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaisavuconazolePharmaceuticalResearch

Edison analysts' take on Basilea outlook

10-09-2012

The protracted development of antibiotic ceftobiprole has left Swiss biotech firm Basilea Pharmaceutica…

Antibiotics and Infectious diseasesBasilea PharmaceuticaBiotechnologyceftobiproleFinancialisavuconazoleOncologyResearchToctino

Back to top